AstraZeneca, Daiichi Sankyo sign $6.9 billion cancer drug deal
Under the deal, AstraZeneca will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development and commercialisation costs for the drug worldwide, with Daiichi retaining exclusive rights in Japan.
U.S: AstraZeneca Plc and Japan's Daiichi Sankyo Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Daiichi's cancer drug trastuzumab deruxtecan.
Under the deal, the drug firm will pay Daiichi up to $6.9 billion, including a $1.35 billion upfront payment. The two companies will share development and commercialisation costs for the drug worldwide, with Daiichi retaining exclusive rights in Japan.
The news sent Daiichi's shares up 16 per cent, its daily limit, in morning Tokyo trading on Friday.
Trastuzumab deruxtecan "has the potential to redefine breast cancer treatment as the first therapy for HER2 low expressing tumors," AstraZeneca Chief Executive Pascal Soriot said in a statement, referring to a type of breast cancer fueled by a protein called HER2.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd